The average gap between NHI prices and the market prices of listed medicines in Japan stood at a preliminary 5.2%…
HOME > BUSINESS
BUSINESS
- Astellas, IBL to Study Manufacturing Method for Agent Utilizing Human Fibrinogen
July 14, 2014
- Takata Seiyaku Looks to Sales of 30 Billion Plus Yen by 2016
July 11, 2014
- Astellas Gearing Up to Expand Xtandi Indication Globally: Chief Medical Officer
July 11, 2014
- Astellas Selects Anticancer FLT3/AXL Inhibitor for Fast-Track Development
July 11, 2014
- Nippon Chemiphar Receives Approval for Actos Generic in Hong Kong: President
July 11, 2014
- Ono to Provide University of Tokyo with Access to Its Compound Library
July 11, 2014
- Bayer Yakuhin Adopts Unique Certificate Program to Train Cancer Sales Reps
July 10, 2014
- Novartis Lays Out New Global Guidelines for Investigator-Led Trials
July 10, 2014
- LSI Medience Develops Cardiotoxicity Assessment System Using Myocardial iPS Cells in NEDO-Driven Research Project
July 10, 2014
- Apeiron Begins PI Study of Neuroblastoma Immunotherapy Agent in Japan
July 10, 2014
- Vital-Net Makes Miyagi-Based Dispensing Pharmacy Chain Ohno its Subsidiary
July 10, 2014
- Bayer Yakuhin Sees Cancer Drugs as New Pillar
July 9, 2014
- MTPC to Up Japan Sales Force by 200-300 Partly via Job Transfers
July 9, 2014
- 31 Executives Received Annual Compensations for FY2013 of Over 100 Million Yen: Jiho Survey
July 9, 2014
- MTPC Aspires to Derive 30% of Sales from Offshore Biz
July 8, 2014
- Sanofi to Bounce Back with New Portfolios, Shift to “Mabs”: Pres.
July 7, 2014
- Sanofi’s Prostate Cancer Drug Cabazitaxel Gets Japan OK
July 7, 2014
- MTPC’s SGLT-2 Inhibitor Canaglu Wins Japan Approval
July 7, 2014
- European Commission Approves Expanded Indication for Halaven for Earlier Use in Breast Cancer Treatment: Eisai
July 7, 2014
- Nippon Kayaku Obtains Approval for Remicade Biosimilar
July 7, 2014
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…